{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T09:19:05Z","timestamp":1783156745776,"version":"3.54.6"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["JR24\/00024"],"award-info":[{"award-number":["JR24\/00024"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejca.2026.116818","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T16:18:17Z","timestamp":1779466697000},"page":"116818","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Association between chemotherapy use and prognosis in young patients with stage I-II ER+\u202f\/HER2-negative breast cancer according to Prosigna\u00ae: An international real-world analysis with propensity-score matching"],"prefix":"10.1016","volume":"242","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6147-9655","authenticated-orcid":false,"given":"Giuseppe","family":"Di Grazia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2124-7534","authenticated-orcid":false,"given":"Vincenzo","family":"Di Lauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2987-3950","authenticated-orcid":false,"given":"Daniel","family":"Morch\u00f3n-Araujo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7092-1785","authenticated-orcid":false,"given":"Sabrina","family":"Nucera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Figuero-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5795-1453","authenticated-orcid":false,"given":"Francisco Javier","family":"Calleja-Holgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pelegrina S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Wallbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Rivera Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2623-4705","authenticated-orcid":false,"given":"Michela","family":"Palleschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7979-6261","authenticated-orcid":false,"given":"Antonino","family":"Musolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gast\u00f3n","family":"Zatta Cobos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assumpci\u00f3","family":"L\u00f3pez Parad\u00eds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6944-5313","authenticated-orcid":false,"given":"Gimena","family":"Barroso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ona","family":"Cano Cano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Dalmau Portulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5952-4333","authenticated-orcid":false,"given":"Aldo","family":"Caltavituro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2829-1455","authenticated-orcid":false,"given":"Giuseppe","family":"Buono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Jerez Gillaranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1156-7681","authenticated-orcid":false,"given":"Isabel","family":"Echavarr\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2606-9538","authenticated-orcid":false,"given":"Sara","family":"L\u00f3pez-Tarruella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milana","family":"Bergamino Sirv\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8686-0236","authenticated-orcid":false,"given":"Olga","family":"Mart\u00ednez-S\u00e1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Adamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Mu\u00f1oz Mateu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4074-2530","authenticated-orcid":false,"given":"Grazia","family":"Arpino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"S\u00e1nchez Bayona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelino","family":"De Laurentiis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar A.","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8431-3183","authenticated-orcid":false,"given":"Tom\u00e1s","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Vidal Losada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6561-1919","authenticated-orcid":false,"given":"Francesco","family":"Schettini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116818_bib1","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","article-title":"Global patterns and trends in breast cancer incidence and mortality across 185 countries","volume":"31","author":"Kim","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2026.116818_bib2","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1158\/0008-5472.CAN-16-2717","article-title":"Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer","volume":"77","author":"Cejalvo","year":"2017","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2026.116818_bib3","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.breast.2015.07.008","article-title":"Clinical implications of the intrinsic molecular subtypes of breast cancer","volume":"24","author":"Prat","year":"2015","journal-title":"Breast"},{"key":"10.1016\/j.ejca.2026.116818_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103900","article-title":"Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives","volume":"181","author":"Sirico","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ejca.2026.116818_bib5","article-title":"Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive\/HER2-negative breast cancer: the NEOENDO translational study\u2729","volume":"9","author":"Schettini","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2026.116818_bib6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2729","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2026.116818_bib7","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/j.breast.2015.07.035","article-title":"Long term side effects of adjuvant chemotherapy in patients with early breast cancer","author":"Tao","year":"2015","journal-title":"Breast"},{"key":"10.1016\/j.ejca.2026.116818_bib8","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1002\/cncr.30547","article-title":"Treatment-associated toxicities reported by patients with early-stage invasive breast cancer","volume":"123","author":"Friese","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2026.116818_bib9","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.116818_bib10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(17)30777-5","article-title":"Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials","volume":"19","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116818_bib11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrclinonc.2011.178","article-title":"Practical implications of gene-expression-based assays for breast oncologists","volume":"9","author":"Prat","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116818_bib12","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","volume":"351","author":"Paik","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116818_bib13","doi-asserted-by":"crossref","first-page":"6012","DOI":"10.1158\/1078-0432.CCR-11-0926","article-title":"A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors","volume":"17","author":"Filipits","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116818_bib14","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","article-title":"Supervised risk predictor of breast cancer based on intrinsic subtypes","volume":"27","author":"Parker","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116818_bib15","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/sj.onc.1209920","article-title":"A gene-expression signature to predict survival in breast cancer across independent data sets","volume":"26","author":"Naderi","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2026.116818_bib16","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.506","article-title":"MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients","volume":"38","author":"Cardoso","year":"2020","journal-title":"JCO"},{"key":"10.1016\/j.ejca.2026.116818_bib17","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116818_bib18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116818_bib19","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S1470-2045(21)00007-3","article-title":"70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age","volume":"22","author":"Piccart","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116818_bib20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41523-025-00738-7","article-title":"Prosigna Risk of Recurrence score and intrinsic subtypes are associated with adjuvant anthracycline chemotherapy benefit in high-risk breast cancer","volume":"11","author":"Jensen","year":"2025","journal-title":"Npj Breast Cancer"},{"key":"10.1016\/j.ejca.2026.116818_bib21","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13058-018-1012-0","article-title":"The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer","volume":"20","author":"Jensen","year":"2018","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ejca.2026.116818_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/npjbcancer.2015.23","article-title":"PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance)","volume":"2","author":"Liu","year":"2016","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ejca.2026.116818_bib23","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221081077","article-title":"Oncotype DX Recurrence Score in premenopausal women","volume":"14","author":"Zhang","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejca.2026.116818_bib24","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1158\/1078-0432.CCR-10-1282","article-title":"A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer","volume":"16","author":"Nielsen","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116818_bib25","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1200\/JCO.2012.46.1558","article-title":"Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy","volume":"31","author":"Dowsett","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116818_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102909","article-title":"First versus second-generation molecular profiling tests: How both can guide decision-making in early-stage hormone-receptor positive breast cancers?","volume":"135","author":"Nguyen Van Long","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2026.116818_bib27","unstructured":"Prosigna instructions for use. English vers. 2025. Veracyte Inc. (San Francisco, CA 94080). Available at: \u3008https:\/\/www.prosigna.com\/resources\/\u3009. Last accessed on 13\/04\/2026."},{"key":"10.1016\/j.ejca.2026.116818_bib28","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1200\/JCO.23.00435","article-title":"Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP","volume":"41","author":"Litton","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116818_bib29","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116818_bib30","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus Endocrine Therapy in Early Breast Cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116818_bib31","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1200\/JCO.20.00853","article-title":"Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study","volume":"39","author":"Buus","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116818_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103451","article-title":"Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy","volume":"69","author":"Chic","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejca.2026.116818_bib33","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.504","article-title":"Evaluation of PAM50 intrinsic subtypes and risk of recurrence (ROR) scores in premenopausal women with early-stage HR+ breast cancer: A secondary analysis of the SOFT trial","volume":"41","author":"Brown","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.ejca.2026.116818_bib34","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2026.116818_bib35","doi-asserted-by":"crossref","unstructured":"Walbaum B., Garc\u00eda-Fructuoso I., Mart\u00ednez-S\u00e1ez O., Schettini F., S\u00e1nchez C., F A., et al. Hormone receptor-positive early breast cancer in young women: A comprehensive review. Cancer Treatment Reviews n.d.;129:102804. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102804.","DOI":"10.1016\/j.ctrv.2024.102804"},{"key":"10.1016\/j.ejca.2026.116818_bib36","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1200\/JCO.2015.65.8013","article-title":"Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival","volume":"34","author":"Partridge","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116818_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35323","article-title":"Characterization of HER2-low breast cancer in young women with germline BRCA1\/2 pathogenetic variants: Results of a large international retrospective cohort study","author":"Schettini","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2026.116818_bib38","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.annonc.2023.01.009","article-title":"Genomic characterisation of hormone receptor-positive breast cancer arising in very young women","volume":"34","author":"Luen","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116818_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105764","article-title":"Genomic and Clinical Features in Young Women with Estrogen Receptor-positive, HER2-negative Breast Cancer","author":"Walbaum","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2026.116818_bib40","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1158\/1078-0432.CCR-16-2092","article-title":"A PAM50-Based Chemoendocrine Score for Hormone Receptor\u2013Positive Breast Cancer with an Intermediate Risk of Relapse","volume":"23","author":"Prat","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116818_bib41","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/CCO.0000000000000892","article-title":"Integrating new oral selective oestrogen receptor degraders in the breast cancer treatment","volume":"34","author":"Garcia-Fructuoso","year":"2022","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ejca.2026.116818_bib42","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/jnci\/djab202","article-title":"The Incidence of Breast Cancer Recurrence 10-32 Years After Primary Diagnosis","volume":"114","author":"Pedersen","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2026.116818_bib43","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1158\/1078-0432.CCR-15-0630","article-title":"Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay","volume":"22","author":"Prat","year":"2016","journal-title":"Clin Cancer Res"}],"updated-by":[{"DOI":"10.1016\/j.ejca.2026.116852","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T00:00:00Z","timestamp":1785024000000}}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492600599X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492600599X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T08:48:31Z","timestamp":1783154911000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492600599X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":43,"alternative-id":["S095980492600599X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116818","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between chemotherapy use and prognosis in young patients with stage I-II ER+\u202f\/HER2-negative breast cancer according to Prosigna\u00ae: An international real-world analysis with propensity-score matching","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116818","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116818"}}